Tags : MeiraGTx

Janssen(J&J) Signs an Exclusive Worldwide License Agreement with MeiraGTx for

Shots: Janssen to get exclusive WW license rights to develop & commercialize certain clinical candidates in MeiraGTx’s inherited retinal disease pipeline. Janssen also has an option to license the portfolio of products for gene targeting in inherited retinal disease, will be developed in collaboration with MeiraGTx The focus of the collaboration is to develop adeno-associated […]Read More

MeiraGTx Acquires Vector Neurosciences to Strengthen its Neurology Portfolio

Shots: Vector’s acquisition is an all-stock transaction including its novel P-II drug candidate AAV-GAD evaluated for Parkinson’s Disease The acquisition focuses on developing candidate AAV-GAD and providing novel treatments for neurological disorders AAV-GAD is a gene therapy candidate delivering glutamic acid decarboxylase (GAD) gene, currently in P-II for Parkinson’s Disease and has also received FTD […]Read More